Omalizumab (Xolair) ( DrugBank: Omalizumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00260702 (ClinicalTrials.gov) | November 24, 2005 | 1/12/2005 | Omalizumab to Treat Hyper-IgE (Job's) Syndrome | Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome | Hyper-IgE Syndrome;Job's Syndrome | Drug: Omalizumab (Xolair) | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 6 Years | 76 Years | All | 1 | Phase 1 | United States |